KREBSBIO

Krebs Biochemicals & Industries Share Price

₹76.9
-2.15 (-2.72%)
08 October, 2024 13:48 BSE: 524518 NSE: KREBSBIO ISIN: INE268B01013

Start SIP in Krebs Biochemicals & Industries

Start SIP

Krebs Biochemicals & Industries Performance

Day Range

  • Low 77
  • High 78
₹ 76

52 Week Range

  • Low 60
  • High 122
₹ 76
  • Open Price0
  • Previous Close78
  • Volume30

Krebs Biochemicals & Industries Chart

  • Over 1 Month -5.38%
  • Over 3 Month + 5.46%
  • Over 6 Month + 4.13%
  • Over 1 Year + 12.76%

Krebs Biochemicals & Industries Key Statistics

P/E Ratio -8.5
PEG Ratio -0.8
Market Cap Cr 166
Price to Book Ratio -1.4
EPS -9.2
Dividend 0
Relative Strength Index 36.78
Money Flow Index
MACD Signal -0.66
Average True Range 2.57

Krebs Biochemicals & Industries Investment Rating

  • Master Rating:
  • Krebs Biocs.& Inds. has an operating revenue of Rs. 52.73 Cr. on a trailing 12-month basis. An annual revenue de-growth of -4% needs improvement, Pre-tax margin of -39% needs improvement, ROE of 0% is poor and needs improvement. NULL The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 25 which is a POOR score indicating inconsistency in earnings, a RS Rating of 34 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 36 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Krebs Biochemicals & Industries Financials
IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 131213151111
Operating Expenses Qtr Cr 151515161316
Operating Profit Qtr Cr -2-3-2-1-3-5
Depreciation Qtr Cr 222221
Interest Qtr Cr 111111
Tax Qtr Cr 000000
Net Profit Qtr Cr -5-6-5-4-5-7
IndicatorMar 2024Mar 2023
Total Revenue Annual Cr 5153
Operating Expenses Annual Cr 5968
Operating Profit Annual in Cr -9-16
Depreciation Cr 77
Interest Annual Cr 53
Tax Annual Cr 00
Net Profit Annual Cr -20-25
IndicatorMar 2024Mar 2023
Cash from Operating Activity Annual Cr 2-25
Cash from Investing Activity Annual Cr -8-13
Cash from Financing Annual Activity Cr 637
Net Cash Flow Annual Cr 00
IndicatorMar 2024Mar 2023
Total ShareHolders Funds Annual Cr 1131
Fixed Assets Annual Cr 152151
Total Non Current Assets Annual Cr 161159
Total Current Assets Annual Cr 1716
Total Assets Annual Cr 178175
IndicatorMar 2024Mar 2023
Book Value Per Share Annual Rs -55-46
ROE Annual % 00
ROCE Annual % -13-17
Total Debt to Total Equity Annual --
EBDIT Annual Margin % -16-29
IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr
Operating Expenses Qtr Cr
Operating Profit Qtr Cr
Depreciation Qtr Cr
Interest Qtr Cr
Tax Qtr Cr
Net Profit Qtr Cr
IndicatorMar 2024Mar 2023
Total Revenue Annual Cr
Operating Expenses Annual Cr
Operating Profit Annual in Cr
Depreciation Cr
Interest Annual Cr
Tax Annual Cr
Net Profit Annual Cr
IndicatorMar 2024Mar 2023
Cash from Operating Activity Annual Cr
Cash from Investing Activity Annual Cr
Cash from Financing Annual Activity Cr
Net Cash Flow Annual Cr
IndicatorMar 2024Mar 2023
Total ShareHolders Funds Annual Cr
Fixed Assets Annual Cr
Total Non Current Assets Annual Cr
Total Current Assets Annual Cr
Total Assets Annual Cr
IndicatorMar 2024Mar 2023
Book Value Per Share Annual Rs
ROE Annual %
ROCE Annual %
Total Debt to Total Equity Annual --
EBDIT Annual Margin %

Krebs Biochemicals & Industries Technicals

EMA & SMA

Current Price
₹76.9
-2.15 (-2.72%)
pointer
  • Bullish Moving Average
  • ___
  • 2
  • Bearish Moving Average
  • ___
  • 14
  • 20 Day
  • ₹83.40
  • 50 Day
  • ₹83.85
  • 100 Day
  • ₹81.53
  • 200 Day
  • ₹79.13
  • 20 Day
  • ₹85.44
  • 50 Day
  • ₹85.25
  • 100 Day
  • ₹80.26
  • 200 Day
  • ₹76.50

Krebs Biochemicals & Industries Resistance and Support

PIVOT
₹78.46
Resistance
First Resistance 78.89
Second Resistance 79.48
Third Resistance 79.91
RSI 36.78
MFI 0.00
MACD Single Line -0.66
MACD -1.80
Support
First Support 77.87
Second Support 77.44
Third Supoort 76.85

Krebs Biochemicals & Industries Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 1,276 127,600 100
Week 2,831 283,050 100
1 Month 11,047 1,104,740 100
6 Month 78,368 2,456,046 31.34

Krebs Biochemicals & Industries Result Highlights

Krebs Biochemicals & Industries Synopsis

Market Cap
Sales
Shares in Float
No of funds
Yield
Book Value
U/D Vol ratio
LTDebt / Equity
Alpha
Beta

Krebs Biochemicals & Industries Shareholding Pattern

Owner Name

Krebs Biochemicals & Industries Management

Name Designation

Krebs Biochemicals & Industries Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Krebs Biochemicals & Industries Corporate Action

Date Purpose Remarks
2024-08-07 Quarterly Results
2024-05-21 Audited Results
2024-02-12 Quarterly Results
2023-11-08 Quarterly Results
2023-08-09 Quarterly Results

Krebs Biochemicals & Industries FAQs

What is Share Price of Krebs Biochemicals & Industries ?

Krebs Biochemicals & Industries share price is ₹76 As on 08 October, 2024 | 13:34

What is the Market Cap of Krebs Biochemicals & Industries ?

The Market Cap of Krebs Biochemicals & Industries is ₹165.8 Cr As on 08 October, 2024 | 13:34

What is the P/E ratio of Krebs Biochemicals & Industries ?

The P/E ratio of Krebs Biochemicals & Industries is -8.5 As on 08 October, 2024 | 13:34

What is the PB ratio of Krebs Biochemicals & Industries ?

The PB ratio of Krebs Biochemicals & Industries is -1.4 As on 08 October, 2024 | 13:34

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23